US.INCY · Incyte

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.644897291104018,
        "turnoverUsdM": 177.90363021000002,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.INCY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 115.7264,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 5.3,
      "take_profit_price": 129.8655,
      "target_multiplier": 1.9,
      "technical_strength": 1.88,
      "take_profit_percent": 6.3
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.289794582208036,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 54.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 51.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 125.878,
    "ma50": 121.7052,
    "close": 122.19,
    "prevClose": 121.47,
    "avgVolume20": 1297053,
    "volumeRatio": 1.12,
    "changePercent": 0.59
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.0359763313609468,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 1.152281082193353,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 0.6577439738581603,
      "volat_points": 0,
      "day_range_pct": 0.01689990997626645,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 54.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 53.33,
        "contribution": 8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 17.1,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 57,
        "contribution": 17.1
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 51.9,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 17.1/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 9.2,
      "市場環境": 8,
      "情緒分析": 4,
      "技術信號": 17.1,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 177.90363021000002,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.INCY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.84
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 714.57349835,
                "ma50": 710.3379992999998,
                "name": "QQQ",
                "close": 709.17999,
                "points": 0.4
              },
              "spy": {
                "ma20": 766.10599295,
                "ma50": 758.9384004200002,
                "name": "SPY",
                "close": 760.88,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.644897291104018,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142141690,
                "url": "https://finnhub.io/api/news?id=c44673cb5a423d969d900d2c2765f99b2937982c87182f53afa88f1de7cd14e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.",
                "category": "company",
                "datetime": 1789412340,
                "headline": "INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?"
              },
              {
                "id": 142137414,
                "url": "https://finnhub.io/api/news?id=e371799cf3ec03c808a7cbfb480d2dde5b32d4db001663b1dc1fbeee97da379c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1789390770,
                "headline": "Incyte (INCY): 3 Reasons We Love This Stock"
              },
              {
                "id": 142062386,
                "url": "https://finnhub.io/api/news?id=cbdf9e44ebf153e16bafde7455595e4489e06365be622abf30df7d147a3d3035",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 9:45 AM EDTCompany ParticipantsWilliam Meury - CEO...",
                "category": "company",
                "datetime": 1789043236,
                "headline": "Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript"
              },
              {
                "id": 142027202,
                "url": "https://finnhub.io/api/news?id=263fdaa9cbb41d995e74a0de94de6961b766a91c507cdbf54c7f612561a4aa9d",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 11:00 AM EDTCompany ParticipantsWilliam Meury - CEO &...",
                "category": "company",
                "datetime": 1788961630,
                "headline": "Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141940129,
                "url": "https://finnhub.io/api/news?id=ed641022f688203b147fe7fa1471c3eecf435dbea2135f60a28ef214ccb06cff",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCYTE CORP (INCY) passes a high growth momentum + technical breakout screen, with strong earnings, ratings of 6/10 momentum, and 10/10 technical setup.",
                "category": "company",
                "datetime": 1788867083,
                "headline": "Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup"
              },
              {
                "id": 141365209,
                "url": "https://finnhub.io/api/news?id=5105efba531f9fb2535ce16988a36b3262b276b7c3a38db894289dcbd60503bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus following renewed attention on upcoming ESMO data for its KRAS G12D inhibitor, known as 734, which is being studied in combination with chemotherapy for pancreatic ductal adenocarcinoma. The renewed focus on Incyte comes after a strong run in the share price, with the latest close at US$124.37 and a 90 day share price return of 30.11%. That move sits within a broader trend where the year to date share price return is 22.63%, while total shareholder return over 1...",
                "category": "company",
                "datetime": 1788098701,
                "headline": "Incyte (INCY) Just Moved, So What Is Drawing Attention Now?"
              },
              {
                "id": 141365210,
                "url": "https://finnhub.io/api/news?id=31be5bd3eb6e61204d49f6616ccf01186bbfed826a67bb4c6e8ad3477e13c0eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS: INCY) is drawing attention as its KRAS G12D inhibitor '734 heads into new data presentations at ESMO, focused on pancreatic ductal adenocarcinoma. The upcoming ESMO readout is expected to support ongoing Phase 3 trials of '734 in pancreatic cancer, a disease area with high unmet medical need. Interest is heightened after a competitor recently received FDA approval for a therapy targeting a similar pathway in oncology. This spotlight on Incyte shows how much investor...",
                "category": "company",
                "datetime": 1788074251,
                "headline": "Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734"
              },
              {
                "id": 141365211,
                "url": "https://finnhub.io/api/news?id=73624c2f9b42de813b38550908858ab02f5f27c1af4f0c82809b06fd6431226e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal […]",
                "category": "company",
                "datetime": 1787955085,
                "headline": "Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?"
              }
            ],
            "raw_source": [
              {
                "id": 142141690,
                "url": "https://finnhub.io/api/news?id=c44673cb5a423d969d900d2c2765f99b2937982c87182f53afa88f1de7cd14e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.",
                "category": "company",
                "datetime": 1789412340,
                "headline": "INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?"
              },
              {
                "id": 142137414,
                "url": "https://finnhub.io/api/news?id=e371799cf3ec03c808a7cbfb480d2dde5b32d4db001663b1dc1fbeee97da379c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1789390770,
                "headline": "Incyte (INCY): 3 Reasons We Love This Stock"
              },
              {
                "id": 142089688,
                "url": "https://finnhub.io/api/news?id=fa78841ae516d242c118f639be92d94e46b09fe684fb41ba03a2c85b445e1854",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
                "category": "company",
                "datetime": 1789150745,
                "headline": "2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off"
              },
              {
                "id": 142085128,
                "url": "https://finnhub.io/api/news?id=95741dde0efa5cad7e611da0864eb37e06641281f8b6e3f001bd71bda1dfc861",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte stock is trading just below a buy zone just as Big Money is giving it the stamp of approval.  Shares popped in July following a strong earnings report that impressed investors.  Incyte stock shows an ideal Composite Rating of 99, boosted by steady year-over-year earnings growth and a decent Relative Strength Rating of 88.",
                "category": "company",
                "datetime": 1789128027,
                "headline": "Profitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On Stock"
              },
              {
                "id": 142115363,
                "url": "https://finnhub.io/api/news?id=759f2770fa321269e8d716d23926c2d80024c876f54cf0000fc45317d7152dcd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of $24.69 billion.",
                "category": "company",
                "datetime": 1789126225,
                "headline": "Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today"
              },
              {
                "id": 142066345,
                "url": "https://finnhub.io/api/news?id=0a89bb8bbdf6e29ec456040b4b7e975b5b537c5f8cb7cf64eefc87ed7086ded0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.",
                "category": "company",
                "datetime": 1789070700,
                "headline": "Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors"
              },
              {
                "id": 142061002,
                "url": "https://finnhub.io/api/news?id=54538e33e8ab33e76186cce9f3759cc966cc32ebf2e0e61c1c61290c43869c3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NYSE: INCY) today announced that MINJUVI® (tafasitamab) in the treatment of relapsed or refractory follicular lymphoma (R/R FL) has been funded in the province of Ontario through Ontario's Funding Accelerated for Specific Treatments (FAST) Program. Through this program, eligible patients may gain access to treatment sooner while formal reimbursement processes continue.1,2",
                "category": "company",
                "datetime": 1789045200,
                "headline": "Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program"
              },
              {
                "id": 142062386,
                "url": "https://finnhub.io/api/news?id=cbdf9e44ebf153e16bafde7455595e4489e06365be622abf30df7d147a3d3035",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 9:45 AM EDTCompany ParticipantsWilliam Meury - CEO...",
                "category": "company",
                "datetime": 1789043236,
                "headline": "Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript"
              },
              {
                "id": 142027202,
                "url": "https://finnhub.io/api/news?id=263fdaa9cbb41d995e74a0de94de6961b766a91c507cdbf54c7f612561a4aa9d",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 11:00 AM EDTCompany ParticipantsWilliam Meury - CEO &...",
                "category": "company",
                "datetime": 1788961630,
                "headline": "Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 142025172,
                "url": "https://finnhub.io/api/news?id=f47919b23f1416ade31c074dd57b0bf69f46b300135f105f8490b9a26f86e126",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314008084/image_1314008084.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "MacroGenics (MGNX) trades below cash with a strong ADC/TCE pipeline and ESMO 2026 catalysts.",
                "category": "company",
                "datetime": 1788948935,
                "headline": "MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead"
              },
              {
                "id": 141940129,
                "url": "https://finnhub.io/api/news?id=ed641022f688203b147fe7fa1471c3eecf435dbea2135f60a28ef214ccb06cff",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCYTE CORP (INCY) passes a high growth momentum + technical breakout screen, with strong earnings, ratings of 6/10 momentum, and 10/10 technical setup.",
                "category": "company",
                "datetime": 1788867083,
                "headline": "Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup"
              },
              {
                "id": 141880520,
                "url": "https://finnhub.io/api/news?id=2b454da8ecc1536e2ee48d239ede2c2c3508ade465316c12f84769f91a08e3c0",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2265725036/image_2265725036.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation outperformed, rising 34% versus the S&P 500's 15% since March 2026. Find out why INCY stock is a Hold.",
                "category": "company",
                "datetime": 1788843461,
                "headline": "Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms"
              },
              {
                "id": 141431780,
                "url": "https://finnhub.io/api/news?id=c212dc388872a3607312857e51ed8ee7ac1abff8186288b14b59c9609958ac93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
                "category": "company",
                "datetime": 1788529570,
                "headline": "2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off"
              },
              {
                "id": 141400653,
                "url": "https://finnhub.io/api/news?id=875032664570c6166afea11a4406f4c881d1eb853fe90b5fdde194d7d17c2561",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449405,
                "headline": "Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?"
              },
              {
                "id": 141374864,
                "url": "https://finnhub.io/api/news?id=ce10dda922ad87853921bc27993702aade129c6db2743b328af3639316380458",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2141587595/image_2141587595.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. See why INCY stock is a Buy.",
                "category": "company",
                "datetime": 1788322299,
                "headline": "Incyte Corporation: Why Jakafi Is No Longer The Real Story Here"
              },
              {
                "id": 141365208,
                "url": "https://finnhub.io/api/news?id=288414dfabfdb4bc07a96be120c7d403b8fe45a22feba07a6ce0011dd87d197d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., September 01, 2026--Incyte to Present at Upcoming Investor Conferences",
                "category": "company",
                "datetime": 1788267600,
                "headline": "Incyte to Present at Upcoming Investor Conferences"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141364578,
                "url": "https://finnhub.io/api/news?id=db1dc8bd97bef642bf3b08ebd399985594b48b71463b04394befe22f506dafbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]",
                "category": "company",
                "datetime": 1788101107,
                "headline": "Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks"
              },
              {
                "id": 141365209,
                "url": "https://finnhub.io/api/news?id=5105efba531f9fb2535ce16988a36b3262b276b7c3a38db894289dcbd60503bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus following renewed attention on upcoming ESMO data for its KRAS G12D inhibitor, known as 734, which is being studied in combination with chemotherapy for pancreatic ductal adenocarcinoma. The renewed focus on Incyte comes after a strong run in the share price, with the latest close at US$124.37 and a 90 day share price return of 30.11%. That move sits within a broader trend where the year to date share price return is 22.63%, while total shareholder return over 1...",
                "category": "company",
                "datetime": 1788098701,
                "headline": "Incyte (INCY) Just Moved, So What Is Drawing Attention Now?"
              },
              {
                "id": 141365210,
                "url": "https://finnhub.io/api/news?id=31be5bd3eb6e61204d49f6616ccf01186bbfed826a67bb4c6e8ad3477e13c0eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS: INCY) is drawing attention as its KRAS G12D inhibitor '734 heads into new data presentations at ESMO, focused on pancreatic ductal adenocarcinoma. The upcoming ESMO readout is expected to support ongoing Phase 3 trials of '734 in pancreatic cancer, a disease area with high unmet medical need. Interest is heightened after a competitor recently received FDA approval for a therapy targeting a similar pathway in oncology. This spotlight on Incyte shows how much investor...",
                "category": "company",
                "datetime": 1788074251,
                "headline": "Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734"
              },
              {
                "id": 141365211,
                "url": "https://finnhub.io/api/news?id=73624c2f9b42de813b38550908858ab02f5f27c1af4f0c82809b06fd6431226e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal […]",
                "category": "company",
                "datetime": 1787955085,
                "headline": "Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?"
              },
              {
                "id": 141365214,
                "url": "https://finnhub.io/api/news?id=93d572f0ffe88c70f01f888a2dc3f94e6d0da03fc98ebdb7a3ab6a3707dc0c32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "uniQure (QURE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1787934629,
                "headline": "Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?"
              },
              {
                "id": 141365215,
                "url": "https://finnhub.io/api/news?id=08b0381568f5ca924cf1bea079266efabc7196cd729013c1c4d7cce2037ac00d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (\"Knight\") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adult",
                "category": "company",
                "datetime": 1787871600,
                "headline": "Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil"
              },
              {
                "id": 141365212,
                "url": "https://finnhub.io/api/news?id=6ff59da84a8345b0319b1cf15d43eca3f37b42cd2f14386ae0cca713f1ae4aa9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1787848214,
                "headline": "Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141329710,
                "url": "https://finnhub.io/api/news?id=c13b34e21f0574f92cecc25925ba4b8bbb47870b616a052134cabcc197b77952",
                "image": "https://www.chartmill.com/images/uploads/minervini_news_8825971f4b.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCYTE (INCY) passes Minervini Trend Template & High Growth screen with strong earnings, sales, RS 93. Setup score 6/10 means wait for better entry.",
                "category": "company",
                "datetime": 1787834495,
                "headline": "Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience"
              },
              {
                "id": 141322438,
                "url": "https://finnhub.io/api/news?id=5b89a111c396ce77d686a5f752a6b55a41ab4baa4c092d77332afe86e3a63eb8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.",
                "category": "company",
                "datetime": 1787731357,
                "headline": "TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)"
              },
              {
                "id": 141318466,
                "url": "https://finnhub.io/api/news?id=d7c7ff30c1b3e55ae13bdb52cc80cbe1f892ae0321e0f9170dd6c952b580763d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2282220392/image_2282220392.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Alex King from Growth Investor Pro discusses the AI cycle, semis and software.",
                "category": "company",
                "datetime": 1787679300,
                "headline": "Don't Sleep On Software"
              },
              {
                "id": 141319860,
                "url": "https://finnhub.io/api/news?id=da328127312b93726b013233096ad00c50ad124e26728165a9c7d87c98790159",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.",
                "category": "company",
                "datetime": 1787585220,
                "headline": "Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?"
              },
              {
                "id": 141300403,
                "url": "https://finnhub.io/api/news?id=423ff622523781f562142ed7b0b7d87cfe74dfb95cf04deb4b282bc564269b75",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2286515404/image_2286515404.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.",
                "category": "company",
                "datetime": 1787464368,
                "headline": "Prelude Therapeutics: A Prognosis After Year-Long Rally"
              },
              {
                "id": 141291858,
                "url": "https://finnhub.io/api/news?id=8ba28b3ef62591be53bd1267edb3588386fb93f48e84c11e7fd4e7edc819225a",
                "image": "",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "",
                "category": "company",
                "datetime": 1787390100,
                "headline": "TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors"
              },
              {
                "id": 141274492,
                "url": "https://finnhub.io/api/news?id=16bd98dd0d2cd72220a3471604976fb19d885131090151f26e69bac8333e7d5e",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $25.75 billion.",
                "category": "company",
                "datetime": 1787254247,
                "headline": "Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years"
              },
              {
                "id": 141274493,
                "url": "https://finnhub.io/api/news?id=baf58b8a3a3b06983aa4287c99be7c1994398570b783f8bed504eb6913278b8f",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Canaccord Genuity  analyst John Newman   initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.",
                "category": "company",
                "datetime": 1787240668,
                "headline": "Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152"
              },
              {
                "id": 141279013,
                "url": "https://finnhub.io/api/news?id=a8bd927ed75c88b5492ec4b6332f4c7ae2352eb289871e0eafb613dfc6f6ee2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took off after Treasury Secretary Bessent announced the Treasury would double its current bond buyback, targeting 10- to 20-year and 20- to 30-year maturities. That sparked an initial big rally, which tapered by the close; still, all of the ... Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Compan",
                "category": "company",
                "datetime": 1787230899,
                "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More"
              },
              {
                "id": 141261028,
                "url": "https://finnhub.io/api/news?id=5b54ec56dfde684c05d3723c87da63c116166a04b8bff3d3ea948663950358c1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2280454849/image_2280454849.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.",
                "category": "company",
                "datetime": 1787212800,
                "headline": "Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance"
              },
              {
                "id": 141263185,
                "url": "https://finnhub.io/api/news?id=4cd5ae836be6f6418eee00221bbef18dcadafba15c22cac06eb43294a6ea0940",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright & Co.  analyst Mitchell S. Kapoor   reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.",
                "category": "company",
                "datetime": 1787211661,
                "headline": "HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target"
              },
              {
                "id": 141275618,
                "url": "https://finnhub.io/api/news?id=2e14a3663cced0c66c160a821e086b59e581ab07ad28e57a62b87130bcadaac1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Wolfe Research identified seven stocks combining strong earnings, rapid sales growth, and positive momentum in a tough market.",
                "category": "company",
                "datetime": 1787208360,
                "headline": "7 Growth Stocks Holding Up in a Tough Market"
              },
              {
                "id": 141255594,
                "url": "https://finnhub.io/api/news?id=3be879eac62e53b8c7ea7ac790ed318cfb5727f57f7db7b32c3dc2c47c2f3ada",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Silence Therapeutics rises on trial results and funding updates; Read on to see Divesiran’s outlook vs. Takeda’s rusfertide competition and analyst views.",
                "category": "company",
                "datetime": 1787152436,
                "headline": "Silence Therapeutics: Making Some Recent Noise"
              },
              {
                "id": 141284452,
                "url": "https://finnhub.io/api/news?id=0eaec1ca73de100ad8399049583950b5de8402dda4c0e4e30e422d646ef4fae7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "While Incyte has outperformed the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1787061045,
                "headline": "Incyte Stock: Is Wall Street Bullish or Bearish?"
              },
              {
                "id": 141238981,
                "url": "https://finnhub.io/api/news?id=46e00c10dc1a4ea0aee1e64048bfd66c65f06433ec62da4433666def96ea0b23",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Piper Sandler  analyst Allison Bratzel   maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.",
                "category": "company",
                "datetime": 1786968688,
                "headline": "Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130"
              },
              {
                "id": 141231125,
                "url": "https://finnhub.io/api/news?id=20166a2b2acd2263cfdbcc99fc419c59e514054bea615fc73fdbae8d84095aeb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445262091/image_1445262091.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.",
                "category": "company",
                "datetime": 1786867596,
                "headline": "IHF: Healthcare Dashboard For August"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 40,
            "discarded_article_count": 30
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.1,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(12.3%→7%)；跌縮量(近10日3日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 1354693.3333333333,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1362750,
              "avg_vol_20": 1263545,
              "avg_vol_30": 1354693.3333333333,
              "range_pct_10": 0.07021851215320402,
              "range_pct_20": 0.10835583926671585,
              "range_pct_30": 0.12300515590473865,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.005947225448318,
              "dist_to_20d_high": 0.06582568807339459,
              "down_shrink_days": 3,
              "breakout_level_20d": 130.8,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.570858283433133
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.644897291104018,
              "turnoverUsdM": 177.90363021000002,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.INCY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 115.7264,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 5.3,
            "take_profit_price": 129.8655,
            "target_multiplier": 1.9,
            "technical_strength": 1.88,
            "take_profit_percent": 6.3
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.289794582208036,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 3.2318,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.64
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -113.18
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0598
    },
    "kdj": {
      "d": 35.09,
      "j": -5.39,
      "k": 21.6,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 34.11
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 14284959,
      "recentSlope": 16115.9,
      "previousSlope": -167940
    },
    "rsi": 38.49,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 129.9404,
      "position": "SAR喺價上",
      "distancePct": 6.34,
      "previousTrend": "下降"
    },
    "ma50": 121.7052,
    "macd": {
      "macd": 0.643400989456552,
      "trend": "中性偏多",
      "signal": 1.573364397070469,
      "histogram": -0.9299634076139169
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 125.591,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.12,
      "score": 6,
      "avgVolume": 1297053,
      "currentVolume": 1455959
    },
    "derived": {
      "ma20": 125.878,
      "ma50": 121.7052,
      "prevClose": 121.47,
      "avgVolume10": 1386836,
      "avgVolume20": 1297053,
      "changePercent": 0.59,
      "avgVolumeForScore": 1297053
    },
    "ma_cross": {
      "ma20": 125.878,
      "ma50": 121.7052,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 125.7765,
      "prevMa50": 121.5986,
      "spreadPct": 3.43,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 121.0317,
      "upper": 130.7243,
      "position": "中間"
    },
    "rsi_short": 22.25,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.12
    }
  }
}

{
  "close": 122.19,
  "volume": 1455959,
  "changePercent": 0.59
}